ID   P63_HUMAN               Reviewed;         680 AA.
AC   Q9H3D4; O75080; O75195; O75922; O76078; Q6VEG2; Q6VEG3; Q6VEG4; Q6VFJ1;
AC   Q6VFJ2; Q6VFJ3; Q6VH20; Q7LDI3; Q7LDI4; Q7LDI5; Q96KR0; Q9H3D2; Q9H3D3;
AC   Q9H3P8; Q9NPH7; Q9P1B4; Q9P1B5; Q9P1B6; Q9P1B7; Q9UBV9; Q9UE10; Q9UP26;
AC   Q9UP27; Q9UP28; Q9UP74;
DT   04-JAN-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   07-APR-2021, entry version 206.
DE   RecName: Full=Tumor protein 63;
DE            Short=p63;
DE   AltName: Full=Chronic ulcerative stomatitis protein;
DE            Short=CUSP;
DE   AltName: Full=Keratinocyte transcription factor KET;
DE   AltName: Full=Transformation-related protein 63;
DE            Short=TP63;
DE   AltName: Full=Tumor protein p73-like;
DE            Short=p73L;
DE   AltName: Full=p40;
DE   AltName: Full=p51;
GN   Name=TP63; Synonyms=KET, P63, P73H, P73L, TP73L;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=9703973; DOI=10.1006/bbrc.1998.9013;
RA   Senoo M., Seki N., Ohira M., Sugano S., Watanabe M., Tachibana M.,
RA   Tanaka T., Shinkai Y., Kato H.;
RT   "A second p53-related protein, p73L, with high homology to p73.";
RL   Biochem. Biophys. Res. Commun. 248:603-607(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Keratinocyte, and Skeletal muscle;
RX   PubMed=9799841; DOI=10.1007/s003359900891;
RA   Augustin M., Bamberger C., Paul D., Schmale H.;
RT   "Cloning and chromosomal mapping of the human p53-related KET gene to
RT   chromosome 3q27 and its murine homolog Ket to mouse chromosome 16.";
RL   Mamm. Genome 9:899-902(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 4 AND 6), NUCLEOTIDE SEQUENCE
RP   [GENOMIC DNA] OF 32-680 (ISOFORMS 1; 3 AND 5), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=9774969; DOI=10.1016/s1097-2765(00)80275-0;
RA   Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Doetsch V.,
RA   Andrews N.C., Caput D., McKeon F.;
RT   "p63, a p53 homolog at 3q27-29, encodes multiple products with
RT   transactivating, death-inducing, and dominant-negative activities.";
RL   Mol. Cell 2:305-316(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 5), VARIANT HEAD AND NECK CANCER
RP   LEU-184, VARIANT LUNG CARCINOMA PRO-187, AND VARIANT CERVICAL CANCER
RP   LEU-204.
RC   TISSUE=Skeletal muscle;
RX   PubMed=9662378; DOI=10.1038/nm0798-839;
RA   Osada M., Ohba M., Kawahara C., Ishioka C., Kanamaru R., Katoh I.,
RA   Ikawa Y., Nimura Y., Nakagawara A., Obinata M., Ikawa S.;
RT   "Cloning and functional analysis of human p51, which structurally and
RT   functionally resembles p53.";
RL   Nat. Med. 4:839-843(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANT COLON CANCER HIS-279, AND
RP   VARIANT OVARIAN CANCER ALA-560.
RX   PubMed=10485447;
RA   Hagiwara K., McMenamin M.G., Miura K., Harris C.C.;
RT   "Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer
RT   cell lines using intronic primers.";
RL   Cancer Res. 59:4165-4169(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=10469295; DOI=10.1046/j.1523-1747.1999.00651.x;
RA   Lee L.A., Walsh P., Prater C.A., Su L.-J., Marchbank A., Egbert T.B.,
RA   Dellavalle R.P., Targoff I.N., Kaufman K.M., Chorzelski T.P., Jablonska S.;
RT   "Characterization of an autoantigen associated with chronic ulcerative
RT   stomatitis: the CUSP autoantigen is a member of the p53 family.";
RL   J. Invest. Dermatol. 113:146-151(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 7), AND ALTERNATIVE
RP   SPLICING (ISOFORM 8).
RX   PubMed=10935472; DOI=10.1038/sj.neo.7900008;
RA   Tani M., Shimizu K., Kawahara C., Kohno T., Ishimoto O., Ikawa S.,
RA   Yokota J.;
RT   "Mutation and expression of the p51 gene in human lung cancer.";
RL   Neoplasia 1:71-79(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 10), AND TISSUE SPECIFICITY (ISOFORM
RP   10).
RX   PubMed=11336476; DOI=10.1054/bjoc.2000.1735;
RA   Senoo M., Tsuchiya I., Matsumura Y., Mori T., Saito Y., Kato H.,
RA   Okamoto T., Habu S.;
RT   "Transcriptional dysregulation of the p73L/p63/p51/p40/KET gene in human
RT   squamous cell carcinomas: expression of Delta Np73L, a novel dominant-
RT   negative isoform, and loss of expression of the potential tumour suppressor
RT   p51.";
RL   Br. J. Cancer 84:1235-1241(2001).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-450 (ISOFORMS 2/4/8), SUBUNIT,
RP   ZINC-BINDING, AND DNA-BINDING.
RC   TISSUE=Prostate;
RX   PubMed=9662346; DOI=10.1038/nm0798-747;
RA   Trink B., Okami K., Wu L., Sriuranpong V., Jen J., Sidransky D.;
RT   "A new human p53 homologue.";
RL   Nat. Med. 4:747-748(1998).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-21; 95-255; 295-330; 378-502 AND
RP   583-680.
RA   Vieira A.R., Murray J.C.;
RT   "Sequencing of candidate genes for non-syndromic cleft lip and palate.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 153-388 (ISOFORM 11).
RC   TISSUE=Placenta;
RX   PubMed=11477076; DOI=10.1074/jbc.m103801200;
RA   Klein C., Georges G., Kunkele K.P., Huber R., Engh R.A., Hansen S.;
RT   "High thermostability and lack of cooperative DNA binding distinguish the
RT   p63 core domain from the homologous tumor suppressor p53.";
RL   J. Biol. Chem. 276:37390-37401(2001).
RN   [13]
RP   SUBUNIT.
RX   PubMed=10373484; DOI=10.1074/jbc.274.26.18709;
RA   Davison T.S., Vagner C., Kaghad M., Ayed A., Caput D., Arrowsmith C.H.;
RT   "p73 and p63 are homotetramers capable of weak heterotypic interactions
RT   with each other but not with p53.";
RL   J. Biol. Chem. 274:18709-18714(1999).
RN   [14]
RP   TISSUE SPECIFICITY.
RX   PubMed=11248048; DOI=10.1073/pnas.061032098;
RA   Pellegrini G., Dellambra E., Golisano O., Martinelli E., Fantozzi I.,
RA   Bondanza S., Ponzin D., McKeon F., De Luca M.;
RT   "p63 identifies keratinocyte stem cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:3156-3161(2001).
RN   [15]
RP   FUNCTION IN NOTCH SIGNALING.
RX   PubMed=11641404; DOI=10.1074/jbc.m108080200;
RA   Sasaki Y., Ishida S., Morimoto I., Yamashita T., Kojima T., Kihara C.,
RA   Tanaka T., Imai K., Nakamura Y., Tokino T.;
RT   "The p53 family member genes are involved in the Notch signal pathway.";
RL   J. Biol. Chem. 277:719-724(2002).
RN   [16]
RP   INTERACTION WITH HIPK2.
RX   PubMed=11925430; DOI=10.1074/jbc.m200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [17]
RP   FUNCTION, DOMAIN, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PHE-55; TRP-59
RP   AND LEU-62.
RX   PubMed=12446779; DOI=10.1128/mcb.22.24.8601-8611.2002;
RA   Serber Z., Lai H.C., Yang A., Ou H.D., Sigal M.S., Kelly A.E.,
RA   Darimont B.D., Duijf P.H.G., Van Bokhoven H., McKeon F., Doetsch V.;
RT   "A C-terminal inhibitory domain controls the activity of p63 by an
RT   intramolecular mechanism.";
RL   Mol. Cell. Biol. 22:8601-8611(2002).
RN   [18]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=12446784; DOI=10.1128/mcb.22.24.8659-8668.2002;
RA   Ghioni P., Bolognese F., Duijf P.H.G., Van Bokhoven H., Mantovani R.,
RA   Guerrini L.;
RT   "Complex transcriptional effects of p63 isoforms: identification of novel
RT   activation and repression domains.";
RL   Mol. Cell. Biol. 22:8659-8668(2002).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH SSRP1.
RX   PubMed=12374749; DOI=10.1093/emboj/cdf540;
RA   Zeng S.X., Dai M.-S., Keller D.M., Lu H.;
RT   "SSRP1 functions as a co-activator of the transcriptional activator p63.";
RL   EMBO J. 21:5487-5497(2002).
RN   [20]
RP   ERRATUM OF PUBMED:12374749.
RA   Zeng S.X., Dai M.-S., Keller D.M., Lu H.;
RL   EMBO J. 23:1679-1679(2004).
RN   [21]
RP   UBIQUITINATION, INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-543.
RX   PubMed=18806757; DOI=10.1038/cdd.2008.134;
RA   Li Y., Zhou Z., Chen C.;
RT   "WW domain-containing E3 ubiquitin protein ligase 1 targets p63
RT   transcription factor for ubiquitin-mediated proteasomal degradation and
RT   regulates apoptosis.";
RL   Cell Death Differ. 15:1941-1951(2008).
RN   [22]
RP   INTERACTION WITH PDS5A.
RX   PubMed=17846787; DOI=10.1007/s00432-007-0306-x;
RA   Zheng M.Z., Zheng L.M., Zeng Y.X.;
RT   "SCC-112 gene is involved in tumor progression and promotes the cell
RT   proliferation in G2/M phase.";
RL   J. Cancer Res. Clin. Oncol. 134:453-462(2008).
RN   [23]
RP   FUNCTION, INTERACTION WITH NOC2L, AND SUBCELLULAR LOCATION.
RX   PubMed=20123734; DOI=10.1093/nar/gkq016;
RA   Heyne K., Willnecker V., Schneider J., Conrad M., Raulf N., Schule R.,
RA   Roemer K.;
RT   "NIR, an inhibitor of histone acetyltransferases, regulates transcription
RT   factor TAp63 and is controlled by the cell cycle.";
RL   Nucleic Acids Res. 38:3159-3171(2010).
RN   [24]
RP   FUNCTION.
RX   PubMed=22197488; DOI=10.1016/j.ajhg.2011.11.013;
RA   Mitchell K., O'Sullivan J., Missero C., Blair E., Richardson R.,
RA   Anderson B., Antonini D., Murray J.C., Shanske A.L., Schutte B.C.,
RA   Romano R.A., Sinha S., Bhaskar S.S., Black G.C., Dixon J., Dixon M.J.;
RT   "Exome sequence identifies RIPK4 as the Bartsocas-Papas syndrome locus.";
RL   Am. J. Hum. Genet. 90:69-75(2012).
RN   [25]
RP   STRUCTURE BY NMR OF 540-610.
RA   Cadot B., Candi E., Cicero D.O., Desideri A., Mele S., Melino G., Paci M.;
RT   "Solution structure of the C-terminal domain of p63.";
RL   Submitted (NOV-2004) to the PDB data bank.
RN   [26]
RP   VARIANTS EEC3 TRP-243; GLN-243 AND ARG-345.
RX   PubMed=10535733; DOI=10.1016/s0092-8674(00)81646-3;
RA   Celli J., Duijf P.H.G., Hamel B.C.J., Bamshad M., Kramer B., Smits A.P.T.,
RA   Newbury-Ecob R., Hennekam R.C.M., Van Buggenhout G., van Haeringen A.,
RA   Woods C.G., van Essen A.J., de Waal R., Vriend G., Haber D.A., Yang A.,
RA   McKeon F., Brunner H.G., van Bokhoven H.;
RT   "Heterozygous germline mutations in the p53 homolog p63 are the cause of
RT   EEC syndrome.";
RL   Cell 99:143-153(1999).
RN   [27]
RP   VARIANTS SHFM4 GLU-233 AND CYS-319, AND VARIANTS EEC3 HIS-318 AND GLN-343.
RX   PubMed=10839977; DOI=10.1086/302972;
RA   Ianakiev P., Kilpatrick M.W., Toudjarska I., Basel D., Beighton P.,
RA   Tsipouras P.;
RT   "Split-hand/split-foot malformation is caused by mutations in the p63 gene
RT   on 3q27.";
RL   Am. J. Hum. Genet. 67:59-66(2000).
RN   [28]
RP   VARIANT ADULT IN NDELTA-TYPE ISOFORMS.
RX   PubMed=11528512; DOI=10.1038/sj.ejhg.5200676;
RA   Amiel J., Bougeard G., Francannet C., Raclin V., Munnich A., Lyonnet S.,
RA   Frebourg T.;
RT   "TP63 gene mutation in ADULT syndrome.";
RL   Eur. J. Hum. Genet. 9:642-645(2001).
RN   [29]
RP   VARIANTS AEC PHE-553 AND GLY-561.
RX   PubMed=11159940; DOI=10.1093/hmg/10.3.221;
RA   McGrath J.A., Duijf P.H.G., Doetsch V., Irvine A.D., de Waal R.,
RA   Vanmolkot K.R., Wessagowit V., Kelly A., Atherton D.J., Griffiths W.A.,
RA   Orlow S.J., van Haeringen A., Ausems M.G., Yang A., McKeon F.,
RA   Bamshad M.A., Brunner H.G., Hamel B.C.J., van Bokhoven H.;
RT   "Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM
RT   domain of p63.";
RL   Hum. Mol. Genet. 10:221-229(2001).
RN   [30]
RP   VARIANTS EEC3 GLN-243; TRP-243; GLN-266; TYR-308; ASN-311; CYS-318;
RP   HIS-318; GLN-318; CYS-319; HIS-319; SER-319; TRP-343; GLN-343; ARG-345;
RP   SER-347; SER-348 AND HIS-351, VARIANTS SHFM4 PRO-193 INS; GLU-232 AND
RP   HIS-319, AND INVOLVEMENT IN LMS.
RX   PubMed=11462173; DOI=10.1086/323123;
RA   van Bokhoven H., Hamel B.C.J., Bamshad M., Sangiorgi E., Gurrieri F.,
RA   Duijf P.H.G., Vanmolkot K.R.J., van Beusekom E., van Beersum S.E.C.,
RA   Celli J., Merkx G.F.M., Tenconi R., Fryns J.-P., Verloes A.,
RA   Newbury-Ecob R.A., Raas-Rotschild A., Majewski F., Beemer F.A., Janecke A.,
RA   Chitayat D., Crisponi G., Kayserili H., Yates J.R.W., Neri G.,
RA   Brunner H.G.;
RT   "p63 gene mutations in EEC syndrome, limb-mammary syndrome, and isolated
RT   split hand-split foot malformation suggest a genotype-phenotype
RT   correlation.";
RL   Am. J. Hum. Genet. 69:481-492(2001).
RN   [31]
RP   VARIANT ADULT SYNDROME GLN-337.
RX   PubMed=11929852; DOI=10.1093/hmg/11.7.799;
RA   Duijf P.H.G., Vanmolkot K.R., Propping P., Friedl W., Krieger E.,
RA   McKeon F., Doetsch V., Brunner H.G., van Bokhoven H.;
RT   "Gain-of-function mutation in ADULT syndrome reveals the presence of a
RT   second transactivation domain in p63.";
RL   Hum. Mol. Genet. 11:799-804(2002).
RN   [32]
RP   VARIANT EEC3 GLY-351.
RX   PubMed=12838557; DOI=10.1002/ajmg.a.20064;
RA   Akahoshi K., Sakazume S., Kosaki K., Ohashi H., Fukushima Y.;
RT   "EEC syndrome type 3 with a heterozygous germline mutation in the P63 gene
RT   and B cell lymphoma.";
RL   Am. J. Med. Genet. A 120:370-373(2003).
RN   [33]
RP   VARIANT RHS HIS-318, AND CHARACTERIZATION OF VARIANT RHS HIS-318.
RX   PubMed=12939657; DOI=10.1038/sj.ejhg.5201004;
RA   Bougeard G., Hadj-Rabia S., Faivre L., Sarafan-Vasseur N., Frebourg T.;
RT   "The Rapp-Hodgkin syndrome results from mutations of the TP63 gene.";
RL   Eur. J. Hum. Genet. 11:700-704(2003).
RN   [34]
RP   VARIANT RHS PRO-580.
RX   PubMed=12766194; DOI=10.1177/154405910308200606;
RA   Kantaputra P.N., Hamada T., Kumchai T., McGrath J.A.;
RT   "Heterozygous mutation in the SAM domain of p63 underlies Rapp-Hodgkin
RT   ectodermal dysplasia.";
RL   J. Dent. Res. 82:433-437(2003).
RN   [35]
RP   VARIANT RHS THR-549.
RX   PubMed=15200513; DOI=10.1111/j.0009-9163.2004.00278.x;
RA   Bertola D.R., Kim C.A., Albano L.M.J., Scheffer H., Meijer R.,
RA   van Bokhoven H.;
RT   "Molecular evidence that AEC syndrome and Rapp-Hodgkin syndrome are
RT   variable expression of a single genetic disorder.";
RL   Clin. Genet. 66:79-80(2004).
RN   [36]
RP   INVOLVEMENT IN OFC8, VARIANT OFC8 GLY-352, AND VARIANTS LEU-129 AND
RP   HIS-603.
RX   PubMed=16740912; DOI=10.1136/jmg.2005.036442;
RA   Leoyklang P., Siriwan P., Shotelersuk V.;
RT   "A mutation of the p63 gene in non-syndromic cleft lip.";
RL   J. Med. Genet. 43:E28-E28(2006).
CC   -!- FUNCTION: Acts as a sequence specific DNA binding transcriptional
CC       activator or repressor. The isoforms contain a varying set of
CC       transactivation and auto-regulating transactivation inhibiting domains
CC       thus showing an isoform specific activity. Isoform 2 activates RIPK4
CC       transcription. May be required in conjunction with TP73/p73 for
CC       initiation of p53/TP53 dependent apoptosis in response to genotoxic
CC       insults and the presence of activated oncogenes. Involved in Notch
CC       signaling by probably inducing JAG1 and JAG2. Plays a role in the
CC       regulation of epithelial morphogenesis. The ratio of DeltaN-type and
CC       TA*-type isoforms may govern the maintenance of epithelial stem cell
CC       compartments and regulate the initiation of epithelial stratification
CC       from the undifferentiated embryonal ectoderm. Required for limb
CC       formation from the apical ectodermal ridge. Activates transcription of
CC       the p21 promoter. {ECO:0000269|PubMed:11641404,
CC       ECO:0000269|PubMed:12374749, ECO:0000269|PubMed:12446779,
CC       ECO:0000269|PubMed:12446784, ECO:0000269|PubMed:20123734,
CC       ECO:0000269|PubMed:22197488, ECO:0000269|PubMed:9774969}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Binds DNA as a homotetramer. Isoform composition of the
CC       tetramer may determine transactivation activity. Isoforms Alpha and
CC       Gamma interact with HIPK2. Interacts with SSRP1, leading to stimulate
CC       coactivator activity. Isoform 1 and isoform 2 interact with WWP1.
CC       Interacts with PDS5A. Isoform 5 (via activation domain) interacts with
CC       NOC2L. {ECO:0000269|PubMed:10373484, ECO:0000269|PubMed:11925430,
CC       ECO:0000269|PubMed:12374749, ECO:0000269|PubMed:17846787,
CC       ECO:0000269|PubMed:18806757, ECO:0000269|PubMed:20123734,
CC       ECO:0000269|PubMed:9662346}.
CC   -!- INTERACTION:
CC       Q9H3D4; P35637: FUS; NbExp=2; IntAct=EBI-2337775, EBI-400434;
CC       Q9H3D4; Q9H2X6: HIPK2; NbExp=2; IntAct=EBI-2337775, EBI-348345;
CC       Q9H3D4; Q99729: HNRNPAB; NbExp=3; IntAct=EBI-2337775, EBI-1044873;
CC       Q9H3D4; P61978: HNRNPK; NbExp=2; IntAct=EBI-2337775, EBI-304185;
CC       Q9H3D4; Q96J02: ITCH; NbExp=2; IntAct=EBI-2337775, EBI-1564678;
CC       Q9H3D4; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-2337775, EBI-348259;
CC       Q9H3D4; Q9UFN0: NIPSNAP3A; NbExp=2; IntAct=EBI-2337775, EBI-716291;
CC       Q9H3D4; Q96FA3: PELI1; NbExp=3; IntAct=EBI-2337775, EBI-448369;
CC       Q9H3D4; Q9HAT8: PELI2; NbExp=3; IntAct=EBI-2337775, EBI-448407;
CC       Q9H3D4; Q13526: PIN1; NbExp=3; IntAct=EBI-2337775, EBI-714158;
CC       Q9H3D4; Q05655: PRKCD; NbExp=2; IntAct=EBI-2337775, EBI-704279;
CC       Q9H3D4; Q15796: SMAD2; NbExp=3; IntAct=EBI-2337775, EBI-1040141;
CC       Q9H3D4; P04637: TP53; NbExp=5; IntAct=EBI-2337775, EBI-366083;
CC       Q9H3D4; Q13625: TP53BP2; NbExp=2; IntAct=EBI-2337775, EBI-77642;
CC       Q9H3D4; Q9H3D4: TP63; NbExp=4; IntAct=EBI-2337775, EBI-2337775;
CC       Q9H3D4; O15350: TP73; NbExp=2; IntAct=EBI-2337775, EBI-389606;
CC       Q9H3D4; P57075-2: UBASH3A; NbExp=3; IntAct=EBI-2337775, EBI-7353612;
CC       Q9H3D4-1; Q8TDN4: CABLES1; NbExp=7; IntAct=EBI-2400586, EBI-604615;
CC       Q9H3D4-1; Q99729: HNRNPAB; NbExp=2; IntAct=EBI-2400586, EBI-1044873;
CC       Q9H3D4-2; Q99729: HNRNPAB; NbExp=2; IntAct=EBI-6481107, EBI-1044873;
CC       Q9H3D4-2; Q9UPW6: SATB2; NbExp=5; IntAct=EBI-6481107, EBI-8298169;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12446779,
CC       ECO:0000269|PubMed:20123734}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=12;
CC       Name=1; Synonyms=TA*-alpha, TAp63alpha, P51B;
CC         IsoId=Q9H3D4-1; Sequence=Displayed;
CC       Name=2; Synonyms=DeltaN-alpha, DeltaNp63 alpha, P51delNalpha;
CC         IsoId=Q9H3D4-2; Sequence=VSP_012465;
CC       Name=3; Synonyms=TA*-beta, TAp63beta;
CC         IsoId=Q9H3D4-3; Sequence=VSP_012470;
CC       Name=4; Synonyms=DeltaN-beta, DeltaNp63 beta, P51delNbeta;
CC         IsoId=Q9H3D4-4; Sequence=VSP_012465, VSP_012470;
CC       Name=5; Synonyms=TA*-gamma, TAp63gamma, P51A;
CC         IsoId=Q9H3D4-5; Sequence=VSP_012468;
CC       Name=6; Synonyms=DeltaN-gamma, DeltaNp63gamma, P51delNgamma;
CC         IsoId=Q9H3D4-6; Sequence=VSP_012465, VSP_012468;
CC       Name=7; Synonyms=TA*-delta, TAp63delta, P51delta;
CC         IsoId=Q9H3D4-7; Sequence=VSP_012469;
CC       Name=8; Synonyms=DeltaN-delta;
CC         IsoId=Q9H3D4-8; Sequence=VSP_012465, VSP_012469;
CC       Name=9; Synonyms=TA*-epsilon;
CC         IsoId=Q9H3D4-9; Sequence=VSP_012466;
CC       Name=10; Synonyms=DeltaN-epsilon, DeltaNp73L;
CC         IsoId=Q9H3D4-10; Sequence=VSP_012465, VSP_012466;
CC       Name=11; Synonyms=P63 delta;
CC         IsoId=Q9H3D4-11; Sequence=VSP_012467;
CC       Name=12;
CC         IsoId=Q9H3D4-12; Sequence=VSP_012465, VSP_012467;
CC   -!- TISSUE SPECIFICITY: Widely expressed, notably in heart, kidney,
CC       placenta, prostate, skeletal muscle, testis and thymus, although the
CC       precise isoform varies according to tissue type. Progenitor cell layers
CC       of skin, breast, eye and prostate express high levels of DeltaN-type
CC       isoforms. Isoform 10 is predominantly expressed in skin squamous cell
CC       carcinomas, but not in normal skin tissues.
CC       {ECO:0000269|PubMed:11248048, ECO:0000269|PubMed:9774969}.
CC   -!- DOMAIN: The transactivation inhibitory domain (TID) can interact with,
CC       and inhibit the activity of the N-terminal transcriptional activation
CC       domain of TA*-type isoforms. {ECO:0000269|PubMed:12446779,
CC       ECO:0000269|PubMed:12446784}.
CC   -!- PTM: May be sumoylated. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated. Polyubiquitination involves WWP1 and leads to
CC       proteasomal degradation of this protein. {ECO:0000269|PubMed:18806757}.
CC   -!- DISEASE: Acro-dermato-ungual-lacrimal-tooth syndrome (ADULT syndrome)
CC       [MIM:103285]: A form of ectodermal dysplasia. Ectodermal dysplasia
CC       defines a heterogeneous group of disorders due to abnormal development
CC       of two or more ectodermal structures. ADULT syndrome involves
CC       ectrodactyly, syndactyly, finger- and toenail dysplasia, hypoplastic
CC       breasts and nipples, intensive freckling, lacrimal duct atresia,
CC       frontal alopecia, primary hypodontia and loss of permanent teeth. ADULT
CC       syndrome differs significantly from EEC3 syndrome by the absence of
CC       facial clefting. Inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:11929852}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC)
CC       [MIM:106260]: An autosomal dominant condition characterized by
CC       congenital ectodermal dysplasia with coarse, wiry, sparse hair,
CC       dystrophic nails, slight hypohidrosis, scalp infections,
CC       ankyloblepharon filiform adnatum, maxillary hypoplasia, hypodontia and
CC       cleft lip/palate. {ECO:0000269|PubMed:11159940}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Ectrodactyly, ectodermal dysplasia, and cleft lip/palate
CC       syndrome 3 (EEC3) [MIM:604292]: A form of ectodermal dysplasia, a
CC       heterogeneous group of disorders due to abnormal development of two or
CC       more ectodermal structures. It is an autosomal dominant syndrome
CC       characterized by ectrodactyly of hands and feet, ectodermal dysplasia
CC       and facial clefting. {ECO:0000269|PubMed:10535733,
CC       ECO:0000269|PubMed:10839977, ECO:0000269|PubMed:11462173,
CC       ECO:0000269|PubMed:12838557}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Split-hand/foot malformation 4 (SHFM4) [MIM:605289]: A limb
CC       malformation involving the central rays of the autopod and presenting
CC       with syndactyly, median clefts of the hands and feet, and aplasia
CC       and/or hypoplasia of the phalanges, metacarpals, and metatarsals. Some
CC       patients have been found to have mental retardation, ectodermal and
CC       craniofacial findings, and orofacial clefting.
CC       {ECO:0000269|PubMed:10839977, ECO:0000269|PubMed:11462173}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Limb-mammary syndrome (LMS) [MIM:603543]: Characterized by
CC       ectrodactyly, cleft palate and mammary-gland abnormalities.
CC       {ECO:0000269|PubMed:11462173}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in TP63 are a cause of cervical, colon, head and
CC       neck, lung and ovarian cancers.
CC   -!- DISEASE: Rapp-Hodgkin syndrome (RHS) [MIM:129400]: A form of ectodermal
CC       dysplasia, a heterogeneous group of disorders due to abnormal
CC       development of two or more ectodermal structures. Characterized by the
CC       combination of anhidrotic ectodermal dysplasia, cleft lip, and cleft
CC       palate. The clinical syndrome is comprised of a characteristic facies
CC       (narrow nose and small mouth), wiry, slow-growing, and uncombable hair,
CC       sparse eyelashes and eyebrows, obstructed lacrimal puncta/epiphora,
CC       bilateral stenosis of external auditory canals, microsomia, hypodontia,
CC       cone-shaped incisors, enamel hypoplasia, dystrophic nails, and cleft
CC       lip/cleft palate. RHS inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:12766194, ECO:0000269|PubMed:12939657,
CC       ECO:0000269|PubMed:15200513}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Orofacial cleft 8 (OFC8) [MIM:618149]: A birth defect
CC       consisting of cleft lips with or without cleft palate. Cleft lips are
CC       associated with cleft palate in two-third of cases. A cleft lip can
CC       occur on one or both sides and range in severity from a simple notch in
CC       the upper lip to a complete opening in the lip extending into the floor
CC       of the nostril and involving the upper gum.
CC       {ECO:0000269|PubMed:16740912}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 1]: Produced by alternative promoter usage.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing of isoform
CC       2. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Produced by alternative splicing of isoform
CC       2. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative splicing of isoform
CC       2. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 9]: Produced by alternative splicing of isoform
CC       1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 10]: Produced by alternative splicing of
CC       isoform 2. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 11]: Produced by alternative splicing of
CC       isoform 1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 12]: Produced by alternative splicing of
CC       isoform 2. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF43486.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF43487.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF43488.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF43489.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=AAF61624.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAA32592.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAA32593.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TP63ID365ch3q27.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB010153; BAA32433.1; -; mRNA.
DR   EMBL; Y16961; CAA76562.1; -; mRNA.
DR   EMBL; AF075428; AAC62633.1; -; mRNA.
DR   EMBL; AF075429; AAC62634.1; -; mRNA.
DR   EMBL; AF075430; AAC62635.1; -; mRNA.
DR   EMBL; AF075431; AAC62636.1; -; mRNA.
DR   EMBL; AF075432; AAC62637.1; -; mRNA.
DR   EMBL; AF075433; AAC62638.1; -; mRNA.
DR   EMBL; AF124539; AAG45607.1; -; Genomic_DNA.
DR   EMBL; AF124528; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124529; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124536; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124537; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124538; AAG45607.1; JOINED; Genomic_DNA.
DR   EMBL; AF124539; AAG45608.1; -; Genomic_DNA.
DR   EMBL; AF124528; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124529; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124536; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124537; AAG45608.1; JOINED; Genomic_DNA.
DR   EMBL; AF124540; AAG45609.1; -; Genomic_DNA.
DR   EMBL; AF124528; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124529; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45609.1; JOINED; Genomic_DNA.
DR   EMBL; AF124539; AAG45610.1; -; Genomic_DNA.
DR   EMBL; AF124530; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124536; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124537; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124538; AAG45610.1; JOINED; Genomic_DNA.
DR   EMBL; AF124539; AAG45611.1; -; Genomic_DNA.
DR   EMBL; AF124530; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124531; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124536; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124537; AAG45611.1; JOINED; Genomic_DNA.
DR   EMBL; AF124540; AAG45612.1; -; Genomic_DNA.
DR   EMBL; AF124531; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124533; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124535; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124534; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124532; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AF124530; AAG45612.1; JOINED; Genomic_DNA.
DR   EMBL; AB016072; BAA32592.1; ALT_FRAME; mRNA.
DR   EMBL; AB016073; BAA32593.1; ALT_FRAME; mRNA.
DR   EMBL; AF091627; AAC43038.1; -; mRNA.
DR   EMBL; AF116770; AAF43486.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF116756; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116757; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43486.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43487.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF116756; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116757; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116767; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116768; AAF43487.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43488.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF116756; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116757; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116767; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43488.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43489.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF116756; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116757; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43489.1; JOINED; Genomic_DNA.
DR   EMBL; AF116770; AAF43490.1; -; Genomic_DNA.
DR   EMBL; AF116758; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43490.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43491.1; -; Genomic_DNA.
DR   EMBL; AF116758; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116768; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116767; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43491.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43492.1; -; Genomic_DNA.
DR   EMBL; AF116758; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116767; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43492.1; JOINED; Genomic_DNA.
DR   EMBL; AF116769; AAF43493.1; -; Genomic_DNA.
DR   EMBL; AF116758; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116760; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116759; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116761; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116763; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116765; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116766; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116764; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116762; AAF43493.1; JOINED; Genomic_DNA.
DR   EMBL; AF116771; AAF61624.1; ALT_FRAME; mRNA.
DR   EMBL; AB042841; BAB20591.1; -; mRNA.
DR   EMBL; BC039815; AAH39815.1; -; mRNA.
DR   EMBL; AF061512; AAC24830.1; -; mRNA.
DR   EMBL; AY342152; AAQ63448.1; -; Genomic_DNA.
DR   EMBL; AY341145; AAQ63448.1; JOINED; Genomic_DNA.
DR   EMBL; AY339663; AAQ63449.1; -; Genomic_DNA.
DR   EMBL; AY341143; AAQ63450.1; -; Genomic_DNA.
DR   EMBL; AY339664; AAQ63450.1; JOINED; Genomic_DNA.
DR   EMBL; AY341142; AAQ63450.1; JOINED; Genomic_DNA.
DR   EMBL; AY341143; AAQ63451.1; -; Genomic_DNA.
DR   EMBL; AY341142; AAQ63451.1; JOINED; Genomic_DNA.
DR   EMBL; AY341144; AAQ63452.1; -; Genomic_DNA.
DR   EMBL; AY342153; AAQ63453.1; -; Genomic_DNA.
DR   EMBL; AY342154; AAQ63454.1; -; Genomic_DNA.
DR   EMBL; AJ315499; CAC48053.1; -; mRNA.
DR   CCDS; CCDS3293.1; -. [Q9H3D4-1]
DR   CCDS; CCDS46976.1; -. [Q9H3D4-3]
DR   CCDS; CCDS46977.1; -. [Q9H3D4-5]
DR   CCDS; CCDS46978.1; -. [Q9H3D4-2]
DR   CCDS; CCDS46979.1; -. [Q9H3D4-4]
DR   CCDS; CCDS46980.1; -. [Q9H3D4-6]
DR   CCDS; CCDS82887.1; -. [Q9H3D4-11]
DR   CCDS; CCDS87179.1; -. [Q9H3D4-7]
DR   CCDS; CCDS87180.1; -. [Q9H3D4-8]
DR   CCDS; CCDS87181.1; -. [Q9H3D4-10]
DR   RefSeq; NP_001108450.1; NM_001114978.1. [Q9H3D4-3]
DR   RefSeq; NP_001108451.1; NM_001114979.1. [Q9H3D4-5]
DR   RefSeq; NP_001108452.1; NM_001114980.1. [Q9H3D4-2]
DR   RefSeq; NP_001108453.1; NM_001114981.1. [Q9H3D4-4]
DR   RefSeq; NP_001108454.1; NM_001114982.1. [Q9H3D4-6]
DR   RefSeq; NP_001316073.1; NM_001329144.1. [Q9H3D4-7]
DR   RefSeq; NP_001316074.1; NM_001329145.1. [Q9H3D4-8]
DR   RefSeq; NP_001316075.1; NM_001329146.1. [Q9H3D4-10]
DR   RefSeq; NP_001316077.1; NM_001329148.1. [Q9H3D4-11]
DR   RefSeq; NP_003713.3; NM_003722.4. [Q9H3D4-1]
DR   RefSeq; XP_016862876.1; XM_017007387.1.
DR   PDB; 1RG6; NMR; -; A=540-614.
DR   PDB; 2NB1; NMR; -; A/C=397-455.
DR   PDB; 2RMN; NMR; -; A=153-388.
DR   PDB; 2Y9T; NMR; -; A=543-622.
DR   PDB; 2Y9U; X-ray; 1.60 A; A=545-611.
DR   PDB; 3QYM; X-ray; 3.20 A; A/B/C/D/E/F/G/H=166-362.
DR   PDB; 3QYN; X-ray; 2.50 A; A/B/C/D=166-362.
DR   PDB; 3US0; X-ray; 2.50 A; A/B/C/D=166-362.
DR   PDB; 3US1; X-ray; 2.80 A; A/D=166-362.
DR   PDB; 3US2; X-ray; 4.20 A; A/B/C/D/G/H/I/J=166-362.
DR   PDB; 3ZY0; X-ray; 1.90 A; A/B/C/D=398-427.
DR   PDB; 3ZY1; X-ray; 2.15 A; A=398-441.
DR   PDB; 4A9Z; X-ray; 2.29 A; A/B/C/D=397-455.
DR   PDB; 6FGN; NMR; -; A=47-73.
DR   PDB; 6RU6; X-ray; 2.05 A; C=618-630.
DR   PDB; 6RU7; X-ray; 2.08 A; C/D=618-633.
DR   PDB; 6RU8; X-ray; 1.92 A; E/F/G/H=621-632.
DR   PDBsum; 1RG6; -.
DR   PDBsum; 2NB1; -.
DR   PDBsum; 2RMN; -.
DR   PDBsum; 2Y9T; -.
DR   PDBsum; 2Y9U; -.
DR   PDBsum; 3QYM; -.
DR   PDBsum; 3QYN; -.
DR   PDBsum; 3US0; -.
DR   PDBsum; 3US1; -.
DR   PDBsum; 3US2; -.
DR   PDBsum; 3ZY0; -.
DR   PDBsum; 3ZY1; -.
DR   PDBsum; 4A9Z; -.
DR   PDBsum; 6FGN; -.
DR   PDBsum; 6RU6; -.
DR   PDBsum; 6RU7; -.
DR   PDBsum; 6RU8; -.
DR   BMRB; Q9H3D4; -.
DR   SMR; Q9H3D4; -.
DR   BioGRID; 114181; 288.
DR   DIP; DIP-29588N; -.
DR   ELM; Q9H3D4; -.
DR   IntAct; Q9H3D4; 90.
DR   MINT; Q9H3D4; -.
DR   STRING; 9606.ENSP00000264731; -.
DR   iPTMnet; Q9H3D4; -.
DR   PhosphoSitePlus; Q9H3D4; -.
DR   BioMuta; TP63; -.
DR   DMDM; 57013009; -.
DR   MassIVE; Q9H3D4; -.
DR   MaxQB; Q9H3D4; -.
DR   PaxDb; Q9H3D4; -.
DR   PeptideAtlas; Q9H3D4; -.
DR   PRIDE; Q9H3D4; -.
DR   ProteomicsDB; 80692; -. [Q9H3D4-1]
DR   ProteomicsDB; 80693; -. [Q9H3D4-10]
DR   ProteomicsDB; 80694; -. [Q9H3D4-11]
DR   ProteomicsDB; 80695; -. [Q9H3D4-12]
DR   ProteomicsDB; 80696; -. [Q9H3D4-2]
DR   ProteomicsDB; 80697; -. [Q9H3D4-3]
DR   ProteomicsDB; 80698; -. [Q9H3D4-4]
DR   ProteomicsDB; 80699; -. [Q9H3D4-5]
DR   ProteomicsDB; 80700; -. [Q9H3D4-6]
DR   ProteomicsDB; 80701; -. [Q9H3D4-7]
DR   ProteomicsDB; 80702; -. [Q9H3D4-8]
DR   ProteomicsDB; 80703; -. [Q9H3D4-9]
DR   Antibodypedia; 1750; 1010 antibodies.
DR   DNASU; 8626; -.
DR   Ensembl; ENST00000264731; ENSP00000264731; ENSG00000073282. [Q9H3D4-1]
DR   Ensembl; ENST00000320472; ENSP00000317510; ENSG00000073282. [Q9H3D4-7]
DR   Ensembl; ENST00000354600; ENSP00000346614; ENSG00000073282. [Q9H3D4-2]
DR   Ensembl; ENST00000392460; ENSP00000376253; ENSG00000073282. [Q9H3D4-3]
DR   Ensembl; ENST00000392461; ENSP00000376254; ENSG00000073282. [Q9H3D4-8]
DR   Ensembl; ENST00000392463; ENSP00000376256; ENSG00000073282. [Q9H3D4-4]
DR   Ensembl; ENST00000418709; ENSP00000407144; ENSG00000073282. [Q9H3D4-5]
DR   Ensembl; ENST00000437221; ENSP00000392488; ENSG00000073282. [Q9H3D4-6]
DR   Ensembl; ENST00000440651; ENSP00000394337; ENSG00000073282. [Q9H3D4-11]
DR   Ensembl; ENST00000449992; ENSP00000387839; ENSG00000073282. [Q9H3D4-10]
DR   Ensembl; ENST00000456148; ENSP00000389485; ENSG00000073282. [Q9H3D4-12]
DR   GeneID; 8626; -.
DR   KEGG; hsa:8626; -.
DR   UCSC; uc003frx.3; human. [Q9H3D4-1]
DR   CTD; 8626; -.
DR   DisGeNET; 8626; -.
DR   GeneCards; TP63; -.
DR   GeneReviews; TP63; -.
DR   HGNC; HGNC:15979; TP63.
DR   HPA; ENSG00000073282; Tissue enhanced (skeletal muscle, skin).
DR   MalaCards; TP63; -.
DR   MIM; 103285; phenotype.
DR   MIM; 106260; phenotype.
DR   MIM; 129400; phenotype.
DR   MIM; 603273; gene.
DR   MIM; 603543; phenotype.
DR   MIM; 604292; phenotype.
DR   MIM; 605289; phenotype.
DR   MIM; 618149; phenotype.
DR   neXtProt; NX_Q9H3D4; -.
DR   OpenTargets; ENSG00000073282; -.
DR   Orphanet; 978; ADULT syndrome.
DR   Orphanet; 1071; Ankyloblepharon-ectodermal defects-cleft lip/palate syndrome.
DR   Orphanet; 93930; Bladder exstrophy.
DR   Orphanet; 141291; Cleft lip and alveolus.
DR   Orphanet; 199306; Cleft lip/palate.
DR   Orphanet; 1896; EEC syndrome.
DR   Orphanet; 199302; Isolated cleft lip.
DR   Orphanet; 2440; Isolated split hand-split foot malformation.
DR   Orphanet; 69085; Limb-mammary syndrome.
DR   PharmGKB; PA162406776; -.
DR   VEuPathDB; HostDB:ENSG00000073282.12; -.
DR   eggNOG; ENOG502QQ48; Eukaryota.
DR   GeneTree; ENSGT00950000183153; -.
DR   HOGENOM; CLU_019621_1_0_1; -.
DR   InParanoid; Q9H3D4; -.
DR   OMA; ELSDPMW; -.
DR   PhylomeDB; Q9H3D4; -.
DR   TreeFam; TF106101; -.
DR   PathwayCommons; Q9H3D4; -.
DR   Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain.
DR   Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases.
DR   Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   SignaLink; Q9H3D4; -.
DR   SIGNOR; Q9H3D4; -.
DR   BioGRID-ORCS; 8626; 42 hits in 1010 CRISPR screens.
DR   ChiTaRS; TP63; human.
DR   EvolutionaryTrace; Q9H3D4; -.
DR   GeneWiki; TP63; -.
DR   GenomeRNAi; 8626; -.
DR   Pharos; Q9H3D4; Tbio.
DR   PRO; PR:Q9H3D4; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9H3D4; protein.
DR   Bgee; ENSG00000073282; Expressed in skin of abdomen and 157 other tissues.
DR   ExpressionAtlas; Q9H3D4; baseline and differential.
DR   Genevisible; Q9H3D4; HS.
DR   GO; GO:0000785; C:chromatin; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IEA:GOC.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IEA:Ensembl.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; NAS:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IMP:CAFA.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0042802; F:identical protein binding; IPI:UniProtKB.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IPI:CAFA.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0002039; F:p53 binding; IPI:CAFA.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:GO_Central.
DR   GO; GO:0050699; F:WW domain binding; IPI:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0007569; P:cell aging; IEA:Ensembl.
DR   GO; GO:0008283; P:cell population proliferation; IEA:Ensembl.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; IEA:Ensembl.
DR   GO; GO:0060197; P:cloacal septation; IEA:Ensembl.
DR   GO; GO:1904888; P:cranial skeletal system development; IEA:Ensembl.
DR   GO; GO:0007499; P:ectoderm and mesoderm interaction; IEA:Ensembl.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0010481; P:epidermal cell division; IEA:Ensembl.
DR   GO; GO:0002064; P:epithelial cell development; IEA:Ensembl.
DR   GO; GO:0001736; P:establishment of planar polarity; IEA:Ensembl.
DR   GO; GO:0061436; P:establishment of skin barrier; ISS:UniProtKB.
DR   GO; GO:0048807; P:female genitalia morphogenesis; IEA:Ensembl.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0010259; P:multicellular organism aging; IEA:Ensembl.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IMP:UniProtKB.
DR   GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0045617; P:negative regulation of keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:2000381; P:negative regulation of mesoderm development; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0030859; P:polarized epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:1902808; P:positive regulation of cell cycle G1/S phase transition; IMP:UniProtKB.
DR   GO; GO:2000271; P:positive regulation of fibroblast apoptotic process; IDA:UniProtKB.
DR   GO; GO:0010838; P:positive regulation of keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:BHF-UCL.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:1904674; P:positive regulation of somatic stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:0060513; P:prostatic bud formation; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:0043281; P:regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0010482; P:regulation of epidermal cell division; ISS:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR   GO; GO:0043589; P:skin morphogenesis; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0060529; P:squamous basal epithelial stem cell differentiation involved in prostate gland acinus development; IEA:Ensembl.
DR   GO; GO:0048485; P:sympathetic nervous system development; IEA:Ensembl.
DR   CDD; cd08367; P53; 1.
DR   CDD; cd09572; SAM_tumor-p63; 1.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR032645; Tp63.
DR   InterPro; IPR037611; Tumor-p63_SAM.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   PANTHER; PTHR11447:SF8; PTHR11447:SF8; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SMART; SM00454; SAM; 1.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative promoter usage; Alternative splicing;
KW   Apoptosis; Developmental protein; Disease variant; DNA-binding;
KW   Ectodermal dysplasia; Isopeptide bond; Metal-binding;
KW   Notch signaling pathway; Nucleus; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc.
FT   CHAIN           1..680
FT                   /note="Tumor protein 63"
FT                   /id="PRO_0000185729"
FT   DOMAIN          541..607
FT                   /note="SAM"
FT   DNA_BIND        170..362
FT   REGION          1..107
FT                   /note="Transcription activation"
FT   REGION          352..388
FT                   /note="Interaction with HIPK2"
FT                   /evidence="ECO:0000269|PubMed:11925430"
FT   REGION          394..443
FT                   /note="Oligomerization"
FT   REGION          610..680
FT                   /note="Transactivation inhibition"
FT   COMPBIAS        437..444
FT                   /note="Poly-Gln"
FT   METAL           244
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           247
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           308
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   METAL           312
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        676
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..108
FT                   /note="MNFETSRCATLQYCPDPYIQRFVETPAHFSWKESYYRSTMSQSTQTNEFLSP
FT                   EVFQHIWDFLEQPICSVQPIDLNFVDEPSEDGATNKIEISMDCIRMQDSDLSDPMW ->
FT                   MLYLENNAQTQFSE (in isoform 2, isoform 4, isoform 6, isoform
FT                   8, isoform 10 and isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:10469295,
FT                   ECO:0000303|PubMed:11336476, ECO:0000303|PubMed:9703973,
FT                   ECO:0000303|PubMed:9774969"
FT                   /id="VSP_012465"
FT   VAR_SEQ         109..193
FT                   /note="Missing (in isoform 9 and isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:11336476"
FT                   /id="VSP_012466"
FT   VAR_SEQ         373..377
FT                   /note="GTKRP -> A (in isoform 11 and isoform 12)"
FT                   /evidence="ECO:0000303|PubMed:11477076"
FT                   /id="VSP_012467"
FT   VAR_SEQ         450..680
FT                   /note="QTSIQSPSSYGNSSPPLNKMNSMNKLPSVSQLINPQQRNALTPTTIPDGMGA
FT                   NIPMMGTHMPMAGDMNGLSPTQALPPPLSMPSTSHCTPPPPYPTDCSIVSFLARLGCSS
FT                   CLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGILDHRQLHEFSSPSHLLRT
FT                   PSSASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMDARRNKQQRIKEE
FT                   GE -> HLLSACFRNELVEPRRETPKQSDVFFRHSKPPNRSVYP (in isoform 5
FT                   and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:9662378,
FT                   ECO:0000303|PubMed:9774969"
FT                   /id="VSP_012468"
FT   VAR_SEQ         503..680
FT                   /note="IPMMGTHMPMAGDMNGLSPTQALPPPLSMPSTSHCTPPPPYPTDCSIVSFLA
FT                   RLGCSSCLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGILDHRQLHEFSSP
FT                   SHLLRTPSSASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMDARRNKQ
FT                   QRIKEEGE -> RSGKSENP (in isoform 7 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:10935472"
FT                   /id="VSP_012469"
FT   VAR_SEQ         551..680
FT                   /note="SFLARLGCSSCLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGIL
FT                   DHRQLHEFSSPSHLLRTPSSASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDF
FT                   NFDMDARRNKQQRIKEEGE -> RIWQV (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:9774969"
FT                   /id="VSP_012470"
FT   VARIANT         129
FT                   /note="S -> L (in dbSNP:rs193287780)"
FT                   /evidence="ECO:0000269|PubMed:16740912"
FT                   /id="VAR_035126"
FT   VARIANT         184
FT                   /note="S -> L (in head and neck cancer)"
FT                   /evidence="ECO:0000269|PubMed:9662378"
FT                   /id="VAR_020866"
FT   VARIANT         187
FT                   /note="A -> P (in lung carcinoma; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:9662378"
FT                   /id="VAR_020867"
FT   VARIANT         193
FT                   /note="T -> TP (in SHFM4)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032736"
FT   VARIANT         204
FT                   /note="Q -> L (in cervical cancer)"
FT                   /evidence="ECO:0000269|PubMed:9662378"
FT                   /id="VAR_020868"
FT   VARIANT         232
FT                   /note="K -> E (in SHFM4; dbSNP:rs1560274243)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032737"
FT   VARIANT         233
FT                   /note="K -> E (in SHFM4; dbSNP:rs121908838)"
FT                   /evidence="ECO:0000269|PubMed:10839977"
FT                   /id="VAR_020869"
FT   VARIANT         243
FT                   /note="R -> Q (in EEC3; dbSNP:rs121908836)"
FT                   /evidence="ECO:0000269|PubMed:10535733,
FT                   ECO:0000269|PubMed:11462173"
FT                   /id="VAR_020870"
FT   VARIANT         243
FT                   /note="R -> W (in EEC3; dbSNP:rs121908835)"
FT                   /evidence="ECO:0000269|PubMed:10535733,
FT                   ECO:0000269|PubMed:11462173"
FT                   /id="VAR_020871"
FT   VARIANT         266
FT                   /note="R -> Q (in EEC3; dbSNP:rs121908849)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032738"
FT   VARIANT         279
FT                   /note="P -> H (in colon cancer)"
FT                   /evidence="ECO:0000269|PubMed:10485447"
FT                   /id="VAR_020872"
FT   VARIANT         308
FT                   /note="C -> Y (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032739"
FT   VARIANT         311
FT                   /note="S -> N (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032740"
FT   VARIANT         318
FT                   /note="R -> C (in EEC3; dbSNP:rs1205536026)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032741"
FT   VARIANT         318
FT                   /note="R -> H (in EEC3 and RHS; does not decrease the
FT                   transcriptional activity of the isoform 5 on a TP53
FT                   reporter system but disrupts the dominant-negative activity
FT                   of isoform 2 and isoform 5 on the transcriptional activity
FT                   of TP53; dbSNP:rs121908840)"
FT                   /evidence="ECO:0000269|PubMed:10839977,
FT                   ECO:0000269|PubMed:11462173, ECO:0000269|PubMed:12939657"
FT                   /id="VAR_020873"
FT   VARIANT         318
FT                   /note="R -> Q (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032742"
FT   VARIANT         319
FT                   /note="R -> C (in EEC3; dbSNP:rs121908839)"
FT                   /evidence="ECO:0000269|PubMed:10839977,
FT                   ECO:0000269|PubMed:11462173"
FT                   /id="VAR_020874"
FT   VARIANT         319
FT                   /note="R -> H (in EEC3 and SHFM4; dbSNP:rs886039442)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032743"
FT   VARIANT         319
FT                   /note="R -> S (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032744"
FT   VARIANT         337
FT                   /note="R -> Q (in ADULT syndrome; confers novel
FT                   transcription activation capacity on isoform 6;
FT                   dbSNP:rs113993967)"
FT                   /evidence="ECO:0000269|PubMed:11929852"
FT                   /id="VAR_020875"
FT   VARIANT         343
FT                   /note="R -> Q (in EEC3; dbSNP:rs121908841)"
FT                   /evidence="ECO:0000269|PubMed:10839977,
FT                   ECO:0000269|PubMed:11462173"
FT                   /id="VAR_020876"
FT   VARIANT         343
FT                   /note="R -> W (in EEC3; dbSNP:rs886041251)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032745"
FT   VARIANT         345
FT                   /note="C -> R (in EEC3; abolishes transcription activation;
FT                   dbSNP:rs121908837)"
FT                   /evidence="ECO:0000269|PubMed:10535733,
FT                   ECO:0000269|PubMed:11462173"
FT                   /id="VAR_020877"
FT   VARIANT         347
FT                   /note="C -> S (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032746"
FT   VARIANT         348
FT                   /note="P -> S (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032747"
FT   VARIANT         351
FT                   /note="D -> G (in EEC3; dbSNP:rs121908844)"
FT                   /evidence="ECO:0000269|PubMed:12838557"
FT                   /id="VAR_020878"
FT   VARIANT         351
FT                   /note="D -> H (in EEC3)"
FT                   /evidence="ECO:0000269|PubMed:11462173"
FT                   /id="VAR_032748"
FT   VARIANT         352
FT                   /note="R -> G (in OFC8; dbSNP:rs121908847)"
FT                   /evidence="ECO:0000269|PubMed:16740912"
FT                   /id="VAR_035127"
FT   VARIANT         549
FT                   /note="I -> T (in RHS; dbSNP:rs121908845)"
FT                   /evidence="ECO:0000269|PubMed:15200513"
FT                   /id="VAR_035128"
FT   VARIANT         553
FT                   /note="L -> F (in AEC; dbSNP:rs121908842)"
FT                   /evidence="ECO:0000269|PubMed:11159940"
FT                   /id="VAR_020879"
FT   VARIANT         560
FT                   /note="S -> A (in ovarian cancer)"
FT                   /evidence="ECO:0000269|PubMed:10485447"
FT                   /id="VAR_020880"
FT   VARIANT         561
FT                   /note="C -> G (in AEC; dbSNP:rs121908843)"
FT                   /evidence="ECO:0000269|PubMed:11159940"
FT                   /id="VAR_020881"
FT   VARIANT         580
FT                   /note="S -> P (in RHS; dbSNP:rs121908846)"
FT                   /evidence="ECO:0000269|PubMed:12766194"
FT                   /id="VAR_035129"
FT   VARIANT         603
FT                   /note="D -> H (in dbSNP:rs767906723)"
FT                   /evidence="ECO:0000269|PubMed:16740912"
FT                   /id="VAR_035130"
FT   MUTAGEN         55
FT                   /note="F->A: Abrogates transcriptional activity and
FT                   interaction with transactivation inhibition domain; when
FT                   associated with A-59 and A-62."
FT                   /evidence="ECO:0000269|PubMed:12446779"
FT   MUTAGEN         59
FT                   /note="W->A: Abrogates transcriptional activity and
FT                   interaction with transactivation inhibition domain; when
FT                   associated with A-55 and A-62."
FT                   /evidence="ECO:0000269|PubMed:12446779"
FT   MUTAGEN         62
FT                   /note="L->A: Abrogates transcriptional activity and
FT                   interaction with transactivation inhibition domain; when
FT                   associated with A-55 and A-59."
FT                   /evidence="ECO:0000269|PubMed:12446779"
FT   MUTAGEN         543
FT                   /note="Y->F: Abolishes ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:18806757"
FT   CONFLICT        125
FT                   /note="Q -> R (in Ref. 1; BAA32433)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        154
FT                   /note="S -> P (in Ref. 1; BAA32433)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        177
FT                   /note="F -> S (in Ref. 1; BAA32433)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        378
FT                   /note="F -> S (in Ref. 10; AAC24830)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        536
FT                   /note="H -> Q (in Ref. 2; CAA76562)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        551
FT                   /note="S -> G (in Ref. 4; BAA32593 and 7; AAF43487/
FT                   AAF43491)"
FT                   /evidence="ECO:0000305"
FT   HELIX           54..63
FT                   /evidence="ECO:0007744|PDB:6FGN"
FT   STRAND          156..161
FT                   /evidence="ECO:0007744|PDB:2RMN"
FT   HELIX           173..175
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          178..180
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          187..189
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          191..195
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   TURN            196..199
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          200..203
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          209..214
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          224..233
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   TURN            234..238
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   HELIX           245..249
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   TURN            252..256
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          263..269
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          274..277
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   TURN            279..281
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          284..289
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          300..306
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   TURN            313..318
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          321..328
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          330..332
FT                   /evidence="ECO:0007744|PDB:3QYM"
FT   STRAND          334..343
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   HELIX           348..355
FT                   /evidence="ECO:0007744|PDB:3QYN"
FT   STRAND          369..372
FT                   /evidence="ECO:0007744|PDB:2RMN"
FT   STRAND          401..407
FT                   /evidence="ECO:0007744|PDB:3ZY0"
FT   HELIX           408..426
FT                   /evidence="ECO:0007744|PDB:3ZY0"
FT   HELIX           429..436
FT                   /evidence="ECO:0007744|PDB:3ZY1"
FT   HELIX           444..449
FT                   /evidence="ECO:0007744|PDB:4A9Z"
FT   STRAND          546..548
FT                   /evidence="ECO:0007744|PDB:2Y9T"
FT   HELIX           549..554
FT                   /evidence="ECO:0007744|PDB:2Y9U"
FT   TURN            555..557
FT                   /evidence="ECO:0007744|PDB:2Y9U"
FT   HELIX           559..561
FT                   /evidence="ECO:0007744|PDB:2Y9U"
FT   HELIX           562..566
FT                   /evidence="ECO:0007744|PDB:2Y9U"
FT   TURN            567..569
FT                   /evidence="ECO:0007744|PDB:2Y9U"
FT   HELIX           573..576
FT                   /evidence="ECO:0007744|PDB:2Y9U"
FT   HELIX           581..586
FT                   /evidence="ECO:0007744|PDB:2Y9U"
FT   HELIX           591..609
FT                   /evidence="ECO:0007744|PDB:2Y9U"
FT   STRAND          613..615
FT                   /evidence="ECO:0007744|PDB:2Y9T"
FT   HELIX           622..625
FT                   /evidence="ECO:0007744|PDB:6RU8"
FT   VARIANT         Q9H3D4-2:6
FT                   /note="N -> H (in ADULT syndrome; dbSNP:rs113993963)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082924"
FT   VARIANT         Q9H3D4-4:6
FT                   /note="N -> H (in ADULT syndrome; dbSNP:rs113993963)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082925"
FT   VARIANT         Q9H3D4-6:6
FT                   /note="N -> H (in ADULT syndrome; dbSNP:rs113993963)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082926"
FT   VARIANT         Q9H3D4-8:6
FT                   /note="N -> H (in ADULT syndrome; dbSNP:rs113993963)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082927"
FT   VARIANT         Q9H3D4-10:6
FT                   /note="N -> H (in ADULT syndrome; dbSNP:rs113993963)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082928"
FT   VARIANT         Q9H3D4-12:6
FT                   /note="N -> H (in ADULT syndrome; dbSNP:rs113993963)"
FT                   /evidence="ECO:0000305"
FT                   /id="VAR_082929"
SQ   SEQUENCE   680 AA;  76785 MW;  F66ECD45E87D9799 CRC64;
     MNFETSRCAT LQYCPDPYIQ RFVETPAHFS WKESYYRSTM SQSTQTNEFL SPEVFQHIWD
     FLEQPICSVQ PIDLNFVDEP SEDGATNKIE ISMDCIRMQD SDLSDPMWPQ YTNLGLLNSM
     DQQIQNGSSS TSPYNTDHAQ NSVTAPSPYA QPSSTFDALS PSPAIPSNTD YPGPHSFDVS
     FQQSSTAKSA TWTYSTELKK LYCQIAKTCP IQIKVMTPPP QGAVIRAMPV YKKAEHVTEV
     VKRCPNHELS REFNEGQIAP PSHLIRVEGN SHAQYVEDPI TGRQSVLVPY EPPQVGTEFT
     TVLYNFMCNS SCVGGMNRRP ILIIVTLETR DGQVLGRRCF EARICACPGR DRKADEDSIR
     KQQVSDSTKN GDGTKRPFRQ NTHGIQMTSI KKRRSPDDEL LYLPVRGRET YEMLLKIKES
     LELMQYLPQH TIETYRQQQQ QQHQHLLQKQ TSIQSPSSYG NSSPPLNKMN SMNKLPSVSQ
     LINPQQRNAL TPTTIPDGMG ANIPMMGTHM PMAGDMNGLS PTQALPPPLS MPSTSHCTPP
     PPYPTDCSIV SFLARLGCSS CLDYFTTQGL TTIYQIEHYS MDDLASLKIP EQFRHAIWKG
     ILDHRQLHEF SSPSHLLRTP SSASTVSVGS SETRGERVID AVRFTLRQTI SFPPRDEWND
     FNFDMDARRN KQQRIKEEGE
//
